FDA recalls GONAK ophthalmic drug solution for manufacturing deviations
Akorn voluntarily recalled 196,254 bottles of GONAK ophthalmic solution nationwide due to CGMP manufacturing practice deviations. This professional-use eye solution is employed in gonioscopic examinations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall initiated by the manufacturer due to CGMP deviations. No illnesses or injuries are reported in the source. The rubric specifies that voluntary precautionary recalls are classified as Moderate.
Plain-English summary
Akorn, Inc. initiated a voluntary recall of GONAK Hypromellose Ophthalmic Demulcent Solution, a professional-use eye drop solution for gonioscopic examinations. The product is supplied in 15 mL dropper bottles containing 2.5% hypromellose (25 mg formulation), with NDC 17478-064-12.
The recall was issued due to Current Good Manufacturing Practice (CGMP) deviations. Akorn initiated the recall on October 13, 2022, and the FDA classified it as a Class II recall on January 13, 2023.
Approximately 196,254 bottles were distributed nationwide in the United States. Multiple lot numbers are affected with expiration dates ranging from January 2023 through November 2023.
This recall remains ongoing. Healthcare professionals and facilities should verify inventory against the provided lot numbers and expiration dates to identify affected products.
The recalled product
- Product
- GONAK Hypromellose Ophthalmic Demulcent Solution, (25 mg) 2.5%, 15 mL per dropper bottle, For Professional Use in Goinoscopic Examinations, Mfd. by: Akorn, INc., Lake Forest, IL 60045. NDC: 17478-064-12
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- Affected units
- 196,254
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 0C80A
- EXP 2/28/2023
- 0B71A
- 1B32A
- EXP 1/31/2023
- 0C80B
- 0F68A
- EXP 5/31/2023
- 0G85A
- 0G01A
- 1G54A
- 1G71A
- EXP 6/30/2023
- 0H32A
- 0H47A
- 1H75A
- EXP 7/31/2023
- 0K22A
- EXP 9/30/2023
- 0M90A
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09